Nilanjan Ghosh, MD, PhD, on Paving the Way for CAR T Therapies in Lymphomas
The chief of the lymphoma division and oncologist at Levine Cancer Institute discussed work that needs to be done to support the use of CAR T therapy.
Nilanjan Ghosh, MD, PhD, on New Avenues of CAR T Research in Lymphoma
The chief of the lymphoma division and oncologist at Levine Cancer Institute discussed new CAR T-cell therapies being investigated for hematologic malignancies.
Nilanjan Ghosh, MD, PhD, on Real-World Efficacy of CAR T-Cell Therapies
The chief of the lymphoma division and oncologist at Levine Cancer Institute discussed data from real-world experience studies.
Improving Access to CAR T-Cell Therapies in Lymphoma: Nilanjan Ghosh, MD, PhD
The chief of the lymphoma division and oncologist at Levine Cancer Institute discussed the impact of CAR T-cell therapies in patients with lymphoma.
Dr. Ghosh on the Potential Advantages of Frontline CAR T-Cell Therapy in DLBCL
Nilanjan Ghosh, MD, PhD, discusses the potential advantages of moving CAR T-cell therapy into the frontline setting for patients with diffuse large B-cell lymphoma.
Dr. Ghosh on Unmet Needs With CAR T-Cell Therapy in DLBCL
Nilanjan Ghosh, MD, PhD, director of the Lymphoma Program and a physician with Levine Cancer Institute, discusses unmet needs with CAR T-cell therapy in diffuse large B-cell lymphoma.
Dr. Ghosh on the Future of CAR T-Cell Therapy in Patients With Hematologic Malignancies
Nilanjan Ghosh, MD, PhD, physician, Levine Cancer Institute, discusses the future of chimeric antigen receptor (CAR) T-cell therapy in the treatment of patients with hematologic malignancies.
